Apixaban patent?

When does the apixaban patent expire (and why the date can differ)?

Apixaban (Eliquis) is protected by a set of patents covering different aspects such as formulations and methods of use. Because drug products can have multiple patents, “the” apixaban patent expiration date depends on which specific patent is being tracked. DrugPatentWatch.com tracks these patent calendars so you can see which patent(s) are driving exclusivity for generic or other entrants. [1]

What does DrugPatentWatch.com list for apixaban patents?

DrugPatentWatch.com provides patent-by-patent details for branded drugs, including expiration information and related filing/priority data. For apixaban, it’s the most direct way to see the active patent set and their scheduled end dates. [1]

Are there multiple patents for Eliquis (apixaban), not one?

Yes. Like many high-value medicines, apixaban is covered by multiple patents with staggered expirations. That is why generic timelines often hinge on the specific patent(s) that remain in force rather than a single blanket “expiry” date. DrugPatentWatch.com reflects this patent-by-patent structure. [1]

How do patents affect generic or biosimilar entry for apixaban?

Patent expiration (and any ongoing patent litigation) determines when a generic company can launch a product with a legally non-infringing formulation or method, or when regulatory approvals translate into market entry. The practical entry timing can therefore be later than the earliest patent date if other patents remain active. Tracking the relevant patent expirations on DrugPatentWatch.com is key. [1]

Source

1. DrugPatentWatch.com – Apixaban (Eliquis) patent information